Long-term consequences in RAS blocker-induced fetopathy with multiorgan impairments.

CEN Case RepOct 26, 2026 (epub)

Hiroshi Komatsu, Tomohiko Imai, Satoru Oya

✦ AI-curated · Sources linked

Case in brief

A girl with fetopathy after maternal exposure to a renin–angiotensin system blocker was followed for 10 years. She had severe short stature and persistent mild developmental delay; cranioplasty at 1 year revealed right frontal lobe hypertrophy. Episodes of marked polyuria caused hypernatremia, with evaluation indicating impaired collecting-duct water reabsorption attributed to aquaporin-2 dysfunction. At age 10, proteinuria prompted kidney biopsy, which showed chronic focal tubulointerstitial injury, hypertrophied remnant glomeruli with segmental sclerosis, and interlobular arterial thickening. Enalapril reduced the proteinuria.

What made this case unusual

The case documents persistent, multiorgan consequences over a decade, including collecting-duct water-handling impairment and chronic renal histologic changes after RAS blocker-induced fetopathy.

Diagnostic / clinical pearl

In RAS blocker-induced fetopathy, later polyuria and hypernatremia may reflect impaired collecting-duct water reabsorption, while proteinuria can accompany chronic renal injury; follow-up in this case identified both.

Why it matters

The reported developmental, growth, water-balance, and renal complications support the authors’ emphasis on long-term follow-up after RAS blocker-induced fetopathy.

Source

Published in CEN Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.